Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ility and edema and prevent the inappropriate growth of new blood vessels in the retina in patients with CRVO.

About VEGF Trap-Eye

VEGF Trap-Eye is a fully human fusion protein, consisting of soluble VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  VEGF Trap-Eye is a specific and highly potent blocker of these growth factors.  VEGF Trap-Eye is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Bayer HealthCare and Regeneron are collaborating on the global development of VEGF Trap-Eye for the treatment of the neovascular form of age related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011. Bayer plans to file regulatory submissions in Europe in the second quarter of 2011.

In April 2011, Bayer HealthCare and Regeneron announced the initiation of a Phase 3 program in DME.

Bayer HealthCare will market VEGF Trap-Eye outside the United States, where the companies will share equally the profits from any future sales of VEGF Trap-Eye.  Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, disease
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 Professional ... in paediatric medicine by awarding the three best ... Formulation initiative (EuPFI) conference . The Formulating ... – 18 in Athens, Greece ... pharmacy students and professionals, from which three winners ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... Md. , Aug. 20, 2014 ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down meth offenders and make ... in Kansas blocked the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... * New study results show more patients receiving ... compared to those taking,either agent alone, EAST HANOVER, ... new study have shown patients taking two Novartis ... the leading therapy Diovan(R) (valsartan) --,experienced greater reductions ...
... -- Cleveland Clinic,researchers today report that the drug ... the "good",cholesterol by more than 60%, did not ... arteries as measured using an,ultrasound probe. , Steven ... and lead investigator of this clinical trial, will,present ...
Cached Medicine Technology:Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 2Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 3Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 4Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 5Tekturna, First New Type of High Blood Pressure Medicine in a,Decade, Provides Additional Blood Pressure Reduction When Used With,Diovan 6Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 2Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 4
(Date:8/21/2014)... TX (PRWEB) August 21, 2014 When children ... of germs that can cause them to become sick and ... practice healthy habits to help them fight these germs to ... and children to do just that with its XFactor program. ... by providing free chewable multi-vitamins. Children ages 4 and up ...
(Date:8/21/2014)... 2014 CarePoint Health is proud ... Patel, MD, and Sujoy Menon, MD, have joined ... and Dr. Menon to the community. CarePoint Health’s ... imaging services to patients in Hudson County through ... Hospital and Hoboken University Medical Center. Our board ...
(Date:8/21/2014)... have developed a genetically engineered line of mice that ... on epilepsy, Alzheimer,s and other diseases. , The ... of fluorescence in response to different calcium levels. This ... and microglia, to be studied in a new way. ... how the brain works," said Petr Tvrdik, Ph.D., ...
(Date:8/21/2014)... Individuals with schizophrenia often have trouble engaging in daily ... study from San Francisco State University suggests the reason ... effort required to complete tasks. , The research, detailed ... Journal of Abnormal Psychology , can assist health professionals ... help those patients function normally by breaking up larger, ...
(Date:8/21/2014)... 2014 According to a new market ... System Market- Global Industry Analysis, Size, Share, Growth, Trends ... market was valued at USD 1,531.2 million in 2013 ... 22.8% from 2013 to 2019, to reach an estimated ... the microfluidic device market is witnessing significant growth due ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Helps with Back to School Preparation 2Health News:Two Top Radiologists Join CarePoint Health 2Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Microfluidic Device System Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3
... 27 Aflac Incorporated,(NYSE: AFL ) announced today ... & Woods 2008 Insurance Conference. President and Chief Financial,Officer ... is,scheduled to make a presentation on September 3, 2008, ... Cloninger will discuss the,company,s outlook for the remainder of ...
... wages and benefits, HEMET, Calif., Aug. 27 The ... against the,board of directors of Valley Health System (VHS) for ... already voted to agree to., "I do this job ... said,Lisa Howell, a registered nurse at Menifee Valley Medical Center. ...
... HARRISBURG, Pa., Aug. 27 Believe it or not,women ... women,s oral,health needs change at different stages throughout their ... Association (PDA) offers a reminder that,understanding these evolving oral ... stage of life, is getting the oral health care ...
... help regain pre-pregnancy body, IRVINE, Calif., ... of post-baby body shaping solution VelaShape(TM),and other ... body,contouring, today reveals the results of the ... women,s desire to regain their,pre-pregnancy body. Syneron ...
... not all part of normal aging process , , WEDNESDAY, Aug. ... women who remain free of dementia will nonetheless undergo an ... years before their death, a new study reveals. , Verbal ... of this cognitive decline, which is not, the researchers stressed, ...
... women quit smoking during pregnancy to protect their unborn children from ... a few months of giving birth. , By shedding light ... that cigarette for good, a study by researchers at the University ... to help women quit and stay quit. , According to the ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:What You Need to Know About Women's Oral Health 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 3Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 4Health News:Mental Skills Can Decline Years Before Dying 2Health News:Mental Skills Can Decline Years Before Dying 3Health News:Newly-defined factors may prevent postpartum smoking relapse 2Health News:Newly-defined factors may prevent postpartum smoking relapse 3
... Mikro-Tip pressure intravascular catheters provide a ... of measuring pressures in the heart ... Mikro-Tip catheters are ideal for high ... in size from 2 to 7 ...
... Millar Mikro-Tip pressure intravascular catheters provide ... method of measuring pressures in the ... thromboresistant Mikro-Tip catheters are ideal for ... range in size from 2 to ...
... Intravascular Mikro-Tip Pressure Catheters; Millar manufactures ... pressure sensor catheters for simultaneous high ... suitable for measuring pressure gradients across ... a vascular stenosis. The catheters are ...
... the United States dying from Sudden Cardiac Death ... recommended that AEDs be used as a standard ... Any AED can provide a life-saving shock during ... continuous monitoring capabilities during and after resuscitation. Plus ...
Medicine Products: